In the years between a warning and a withdrawal, dozens of patients in Britain received a mechanical heart device that NHS data had already marked as far more lethal than its alternative. Two of the country's leading transplant centres — Freeman Hospital in Newcastle and Harefield Hospital in London — continued implanting the Medtronic pump until the manufacturer pulled it from the market in 2021, three years after internal mortality figures had begun to speak plainly. The story of Greg Marshall, a 26-year-old who suffered a stroke, a device failure, and finally cardiac arrest, gives human wei
Daily Mail Online
· Nov 13, 2025
· health
· 3 min de lectura
High
Verificación: Verificado
NHS hospitals continued using heart device with 2.5x higher death rate despite safety concerns
Greg Marshall, a 26-year-old patient, suffered a stroke from the device, experienced device failure, and died unexpectedly in cardiac arrest in 2023; dozens of other patients died at elevated rates.
◉
Health & Medicine
8293 artículos relacionados
Retatrutide: Eli Lilly's Triple-Action Weight-Loss Drug Poised to Resh…
The Economic Times · 100% coincidencia
Next-gen KRAS inhibitor elisrasib shows stronger response rates than f…
Medical Xpress · 99% coincidencia
BioNTech, OncoC4 Report 54% Death Risk Reduction for Lung Cancer Drug …
The Manila Times · 99% coincidencia
mRNA COVID Vaccines Show Survival Boost in Advanced Cancer Patients
Devdiscourse · 99% coincidencia
Amivantamab-lazertinib combo outperforms standard care in high-risk EG…
News-Medical.net · 99% coincidencia
Cobertura Relacionada
7NEWS · Aug 23
Model's Foot Cut Led to Heart Surgery, Baby Loss—Now Advocating for Better Diagnostics
Australian model Leah Ramsey lost her baby after a small foot cut triggered a rare heart infection that was repeatedly m…
Informanté · Aug 23 South Africa Shares FMD Vaccines as Region Strengthens Disease ControlsSouth Africa reports its largest-ever FMD outbreak is coming under control through accelerated vaccination and regional …
Al Jazeera · Aug 23 Solar telemedicine kiosks expand healthcare access across rural ChadSolar-powered telemedicine kiosks in rural Chad enable remote doctor consultations at a fraction of traditional travel c…
Inquirer.net · Aug 23 Prince Harry returns to UK amid family rifts, seeking reconciliation with monarchyPrince Harry and Meghan Markle are relocating back to Britain after six years in California, potentially signaling recon…
Sesgo y Encuadre
⚖
Article uses dramatic framing and selective evidence to portray NHS/hospitals as negligent, emphasizing patient harm while underexploring systemic complexity and decision-making rationale.
Bias Direction
center-right
Confidence
HIGH
Institutional failure narrative with emotional case study anchoring. Opens with accusatory framing ('put patients at risk'), emphasizes timeline of ignored warnings, and uses individual tragedy to personalize systemic critique. Presents binary choice (Medtronic vs. Abbott) without exploring clinical context.
put patients at risk
feared to be linked
despite this
terrified of having another stroke
refused another surgery
emerged
Statements from Freeman Hospital or Harefield Hospital explaining their clinical decision-making
Perspective from Medtronic on the timeline and safety data available to them
Expert cardiologist commentary on why the device may have remained in use (e.g., patient selection criteria, individual case factors)
Context on consultant relationships and whether they influenced decisions or were incidental
Discussion of why 2019 audit data didn't immediately trigger withdrawal
Regulatory/NHS approval process explanation
Impacto Geopolítico
🌎
UK NHS hospitals continued using a Medtronic heart device with 2.5x higher mortality rates despite 2018 safety concerns, raising questions about medical device governance and corporate influence in healthcare decisions.
Escalation Risk
low
Confidence
HIGH
United Kingdom
Europe (regulatory implications)
This reflects institutional power imbalances: corporate interests (Medtronic) maintained influence through consultant relationships with hospital leadership, while regulatory oversight (NHS) lacked enforcement mechanisms to compel device discontinuation despite safety data. Reveals tension between manufacturer interests and patient safety priorities.
Similar to the PIP breast implant scandal (2010-2012) where defective medical devices remained in use despite known risks due to regulatory gaps and manufacturer influence, highlighting recurring failures in medical device oversight across healthcare systems.
Lente Económico
📈
NHS hospitals continued using a Medtronic heart device with 2.5x higher mortality rates despite 2018 safety concerns, raising questions about medical device regulation, manufacturer conflicts of interest, and healthcare accountability.
Market Signal
bearish
Confidence
HIGH
Healthcare/Medical Devices
Pharmaceuticals & Medical Equipment Manufacturing
Insurance (Health/Medical Liability)
Regulatory & Compliance Services
Patients face increased mortality risk from medical devices; reduced trust in NHS device selection processes; potential for higher insurance costs and litigation; patients may demand second opinions and alternative treatments, increasing healthcare costs.
Likely regulatory tightening of medical device approval and monitoring processes; potential mandatory independent safety reviews; stricter conflict-of-interest rules for consultant relationships between hospitals and manufacturers; possible compensation schemes for affected patients; enhanced post-market surveillance requirements.